Bridge to Life Expands EasiSlush® Sodium Chloride Solution Indications with FDA Clearance

Bridge to Life Receives New FDA Clearance for EasiSlush® Sodium Chloride Solution

Bridge to Life™ Ltd., renowned for its innovative organ preservation solutions and perfusion technology, has recently announced a significant milestone in its product offerings. The company garnered 510K Clearance from the U.S. Food and Drug Administration (FDA) for its EasiSlush® Sodium Chloride Solution, which is now approved for use during critical surgical procedures including cardiovascular, abdominal, and transplant surgeries.

This approval marks a pivotal advancement in the usability and application of EasiSlush®, enhancing its role in supporting organ transplant professionals who often operate under stringent timelines to transport organs from donors to recipients. With its unmatched efficiency, EasiSlush® has established itself as a preferred tool for healthcare professionals in the organ transplant field.

CEO Comments on the Expansion

Don Webber, CEO of Bridge to Life, expressed enthusiasm about the FDA's approval, stating, "The 510k clearance for this new indication for our EasiSlush® now provides cardiovascular and abdominal surgeons, as well as transplant surgeons, with greater flexibility in meeting the needs of patients during these surgical procedures." This expansion comes at a time when the demand for effective and reliable organ preservation solutions is heightened, offering professionals the ability to streamline their workflows while ensuring optimal viability of transported organs.

Product Details and Applications

EasiSlush® is specifically designed to create a slushed solution that provides critical hypothermia during the recovery, storage, and transportation of donor organs. Additionally, it also induces regional hypothermia in various surgical contexts, including open-heart surgeries and kidney procedures, by directly applying the slushed solution. Its versatility underscores the product's importance in modern surgical practices, particularly in life-saving procedures.

Bridge to Life's Commitment to Innovation

Bridge to Life™ Ltd. has solidified its standing in the organ preservation landscape by offering high-quality products like Belzer UW®, EasiSlush®, and the VitaSmart™ Hypothermic Oxygenated Perfusion System. The company's commitment to excellence is reflected in its collaborations with leading transplant centers and organ procurement organizations around the globe. The emphasis on product innovation and user accessibility sets Bridge to Life apart in an industry that critically relies on the reliability and effectiveness of these solutions.

Conclusion

With the new FDA approval, EasiSlush® is well-positioned to support not only organ transplant professionals but also cardiovascular and abdominal surgeons, paving the way for enhanced patient care. As technologies in the field of organ preservation continue to evolve, Bridge to Life remains at the forefront, providing cutting-edge solutions to meet the growing demands of healthcare professionals worldwide.

For more details on EasiSlush® and other innovative products from Bridge to Life, visit bridgetolife.com.